Podcasts about liraglutide

Listen in as Jay H. Shubrook, DO, FACOFP, FAAFP, and Chrisopher Weber, MD, FAAP, FACP, CSCS, daBOM, FOMA, discuss the latest advances in caring for patients with overweight or obesity in the primary care setting, including:The Lancet Commission's new obesity definitions and diagnostic criteriaKey data on incretin-based antiobesity medications like semaglutide and tirzepatideBest practices for patient discussionsStrategies for incorporating new evidence in your primary care practicePresentersJay H. Shubrook, DO, FACOFP, FAAFPProfessor and DiabetologistDepartment of Clinical Sciences and Community HealthTouro University California College of Osteopathic MedicineVallejo, CaliforniaChristopher Weber, MD, FAAP, FACP, CSCS, daBOM, FOMABariatric Services Medical Director, Ascension WisconsinObesity Medicine Director, Ascension Columbia St Mary's Bariatric CenterTrustee, Obesity Medicine AssociationAdjunct Assistant Professor of PediatricsMedical College of WisconsinMilwaukee, WisconsinLink to full program:https://bit.ly/4rG7QQp Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Ladies, if you're on a fat loss journey or hormone health journey using GLP-1 medications like semaglutide or liraglutide — and you want the fat loss without feeling like absolute trash — this episode is for you.   I break down the 5 biggest mistakes that are sabotaging your results on GLP-1s, including:   1⃣ Why semaglutide is often the wrong first choice compared to daily liraglutide dosing — and how weekly injections kill natural GLP-1 pulsatility, insulin sensitivity, and appetite control.   2⃣ Skipping microdosing and jumping straight to macro doses, which increases side effects and reduces long-term success.   3⃣ Critically low fiber intake — why 30g/day is non-negotiable and how to use psyllium husk and chia to boost GLP-1 naturally.   4⃣ Not having an exit strategy — reverse dieting, habit restructuring, and how people regain everything when they don't plan their transition.   5⃣ Drinking alcohol like you're not medicated — why GLP-1 + alcohol is a blood-sugar, fat-metabolism, and recovery nightmare.   If you're serious about losing fat on GLP-1s without wrecking your metabolism, gut, hormones, or rebound weight, I've built a full GLP-1 Microdosing Guide that includes:   ✅ Exact microdosing schedule ✅ Full fat-loss meal plan ✅ Full workout plan ✅ Hormone-friendly GLP-1 support strategy   DM me "GLP1" on Instagram and I'll send you the full guide.

Two papers this week, with a bunch of articles that we referenced in the conversation. Also, the last Fortnight podcast was accidentally posted behind a paywall. It is now up and free to listen to. My apologies.Sensible Medicine is reader-supported. If you appreciate our work, consider becoming a free or paid subscriber.Folinic acid improves verbal communication in children with autism and language impairment: a randomized double-blind placebo-controlled trial* Folate Receptor Alpha Autoantibodies in Autism Spectrum Disorders: Diagnosis, Treatment and Prevention* Association Between Maternal Use of Folic Acid Supplements and Risk of Autism Spectrum Disorders in Children* Cerebral folate receptor autoantibodies in autism spectrum disorder* What Is Leucovorin, the Medicine Being Approved for Autism Treatment?* Clinicaltrial.gov searchEffects of Glucagon-Like Peptide 1 Receptor Agonist Initiation in Patients With Heart Failure With Reduced Ejection Fraction and Implantable Cardiac Devices* Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes* Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes* Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction* Increased Risk of Heart Failure Hospitalization With GLP-1 Receptor Agonists in Patients With Reduced Ejection Fraction: A Meta-Analysis of the EXSCEL and FIGHT Trials This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.sensible-med.com/subscribe

THE NATURAL GLP-1 SUPPLEMENT STACK

The FDA has approved a generic version of liraglutide injection, expanding access to obesity treatment by lowering costs and broadening eligibility across adults and adolescents, though safety monitoring remains essential. A JAMA Network Open study found that overweight older adults had lower 30-day mortality after elective surgery compared to those of normal weight, highlighting the “obesity paradox” in surgical risk assessment. Finally, a new rapid, culture-free diagnostic method for sepsis can identify pathogens within two hours using microfluidics and deep learning, offering significant potential to improve survival in critically ill patients.

In this chapter, Dr. Schupbach analyzes the business of healthcare and a way he believes can let patients wage war on the mis-alligned incentives. This is a continuation of our Grand Rounds sequence. Come join Alex and Venk on this adventure! TEASER Specifically, childhood obesity is skyrocketing--1 in 5 children are now above the 95th percentile BMI for age and sex. A recent NEJM article showed Liraglutide (a medication that costs approximately $12,000 per year) was effective in children as young as 6 years old. This is just one example of many where cheap foods, expensive drugs, and band-aid solutions are generating record profits for the most powerful voices at the table. But are we truly acting in the best interests of our patients? What are the unintended consequences of these misaligned incentives? What is our responsibility in all this and where do we start if we want to be part of the solution?

Fat Loss & Metabolism with Dr. Ben Bikman Challenging the dogma surrounding heart disease. (1:32) Is there a connection between dementia and heart disease? (12:05) Strength training and Alzheimer's. (17:49) Learning something new helps put off dementia. (22:45) The connection between insulin resistance and your body's inability to fight off infection. (25:17) We put TOO much attention on total cholesterol. (27:55) Fat cells dynamics explained. (30:13) Why your metabolism is EXTREMELY complex. (44:14) Mitochondrial uncoupling. (48:51) Ketones and athletic performance. (55:39) The problem with DNP. (58:11) Why he is a HUGE advocate of creatine. (1:01:03) The brain loves ketones. (1:04:33) Keep your running shoes in the closet, GO STRENGTH TRAIN! (1:05:32) The metabolic origins of chronic disease. (1:08:10) How GLP-1s are being overused and the proper way to use them. (1:14:48) The resurgence of religion. (1:37:57) As a scientist, did he ever doubt his faith? (1:41:28) The most profound moment of his life. (1:45:51) Related Links/Products Mentioned Why We Get Sick: The Hidden Epidemic at the Root of Most Chronic Disease - and How to Fight It – Book by Dr. Benjamin Bikman How Not to Get Sick: A Cookbook and Guide to Prevent and Reverse Insulin Resistance, Lose Weight, and Fight Chronic Disease – Book by Dr. Benjamin Bikman Unlock sharper focus and support long-term brain health with Ketone-IQ—clean brain fuel for deep work, mental clarity, and sustained energy with no crash. Get 30% off your subscription, plus a free gift with your second shipment at https://ketone.com/MINDPUMP June Special: Shredded Summer Bundle or Bikini Bundle 50% off! ** Code JUNE50 at checkout ** Most heart attack patients' cholesterol levels did not indicate cardiac risk Study: Doubling Saturated Fat in the Diet Does Not Increase Saturated Fat in Blood Insulin signal transduction pathway Mind Pump #1922: Fatphobia & Other Lies That Are Keeping You Fat, Unhealthy & Sick Diabulimia: Why This Eating Disorder Is So Dangerous for People with Diabetes Harris-Benedict equation - Wikipedia Mitochondrial Uncoupling: A Key Controller of Biological Processes in Physiology and Diseases DNP (Dinitrophenol): Overview, Mechanism, and Risks Mind Pump #2497: The Amazing & Weird Side Effects of Creatine Muscle strength and fitness linked to reduction in cancer deaths Fighting Cancer By Putting Tumor Cells On A Diet - NPR Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined Attenuated GLP-1 secretion in obesity: cause or consequence? Mind Pump #2597: Before You Take Ozempic, Wegovy, or Mounjaro Listen to This! Liraglutide modulates lipid metabolism via ZBTB20-LPL pathway Mind Pump #872: Dr. Warren Farrell- The Boy Crisis Mind Pump Podcast – YouTube Mind Pump Free Resources Featured Guest/People Mentioned Benjamin Bikman (@benbikmanphd) Instagram Website Zach Bitter (@zachbitter) Instagram  Thomas N. Seyfried (@thomasseyfriedbc) Instagram Warren Farrell, PhD (@drwarrenfarrell) X/Twitter  

Listen in as Joseph Kim, MD, MPH, MBA; Manish Shah, MD; Martha Grugel, MA, discuss how they manage the prior authorization process for antiobesity agents to improve the quality of their care delivery, including:The information to collect during patient visitsThe available resources to help you submit prior authorizationsThe supporting documents that are often necessary to accompany prior authorizationsHow to address denials and appealsWhen to access manufacturer-based or foundation-based financial assistancePresentersJoseph Kim, MD, MPH, MBAPresidentQ Synthesis, LLCNewtown, PennsylvaniaManish Shah, MDClinical Associate Faculty MS1 PreceptorUniversity of Florida College of MedicineGainesville, FloridaMartha Grugel, MAMedical AssistantWesley Chapel, FloridaLink to full program: https://bit.ly/45P0v8z

“Obesity Rx

This week on Fat Science, Dr. Emily Cooper, Andrea Taylor, and Mark Wright answer listener questions from around the world about metabolic health. This mailbag episode explores widely-debated topics like “starvation mode,” weight loss plateaus, the relationship between metabolism and cognitive health, cannabis and metabolism, metabolic effects of liposuction, and the latest on GLP-1 medications.Key Takeaways:Dr. Cooper dispels myths around “starvation mode,” citing research on the long-term metabolic impact of dieting and caloric restriction.Weight loss plateaus are often misunderstood—Dr. Cooper explains the natural adaptations behind them and how to assess true progress.Metabolic health plays a major role in brain function, cognitive decline, depression, and dementia prevention.Cannabis affects metabolic pathways in complex ways, with regular use potentially causing negative metabolic effects.Liposuction can trigger metabolic rebound and rapid fat regain for some patients, especially when leptin levels are low.Updates on GLP-1 meds: Liraglutide is available in generic form, but costs fluctuate. New oral and combination therapies are on the horizon.Personal Stories & Practical Advice:Andrea and Mark reflect on their own journeys with dieting, weight plateaus, and medication.Dr. Cooper shares clinical experiences with metabolic rebound after liposuction and ways to navigate pharmacologic treatments.Correction: Lilly has a lower cash pay for Medicare and Medicaid, but Novo Nordisk is not yet.References related to diet-induced metabolic adaptation, also called biological adaptation and defense of body weight. 1. Keys, A., Brozek, J., Henschel, A., Mickelsen, O., & Taylor, H. L. (1950). The Biology of Human Starvation. University of Minnesota Press.2. Dulloo, A. G. (2021). Physiology of weight regain: Lessons from the classic Minnesota Starvation Experiment on human body composition regulation. Obesity Reviews, 22, e13189.3. Müller, M. J., & Bosy-Westphal, A. (2013). Adaptive thermogenesis with weight loss in humans. Obesity, 21(2), 218-228.4. Rosenbaum, M., & Leibel, R. L. (2010). Adaptive thermogenesis in humans. International Journal of Obesity, 34(S1), S47-S55.5. Fothergill, E., Guo, J., Howard, L., Kerns, J. C., Knuth, N. D., Brychta, R., ... & Hall, K. D. (2016). Persistent metabolic adaptation 6 years after "The Biggest Loser" competition. Obesity, 24(8), 1612-1619.6. Johanssen, D. L., Knuth, N. D., Huizenga, R., Rood, J., Ravussin, E., & Hall, K. D. (2012). Metabolic slowing with massive weight loss despite preservation of fat-free mass. Journal of Clinical Endocrinology & Metabolism, 97(7), 2489-2496.7. Sumithran, P., Prendergast, L. A., Delbridge, E., Purcell, K., Shulkes, A., Kriketos, A., & Proietto, J. (2011). Long-term persistence of hormonal adaptations to weight loss. New England Journal of Medicine, 365(17), 1597-1604.8. MacLean, P. S., Bergouignan, A., Cornier, M. A., & Jackman, M. R. (2011). Biology's response to dieting: the impetus for weight regain. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 301(3), R581-R600Resources:Connect with Dr. Emily Cooper on LinkedIn.Connect with Mark Wright on LinkedIn.Connect with Andrea Taylor on Instagram.Fat Science is a podcast on a mission to explain where our fat really comes from and why it won't go and stay away. We are committed to creating a world where people are empowered with accurate information about metabolism and recognize that fat isn't a failure. This podcast is for informational purposes only and is not intended to replace professional medical advice.If you have a question for Dr. Cooper, email us at info@diabesityinstitute.org or dr.c@fatsciencepodcast.com.Fat Science is supported by the non-profit Diabesity Institute which is on a mission to increase access to effective, science-based medical care for those suffering from or at risk for diabesity. https://diabesityresearchfoundation.org/

SKIN & WELLNESS APPBLOGMy Epic Semaglutide Taper Journey! Astonishing Ozempic Weight Loss Transformation!Ozempic weight loss before and after. I used semaglutide for six months in 2023 to lose 25 lbs. This is my generic Ozempic dosage, how I tapered off, and how much weight I lost over six months.In this video, Ozempic weight loss before and after I share my Ozempic semaglutide dosage and taper calendar, plus a ton of photos and what I'm doing after using Ozempic. This is my semaglutide taper experience. If you can relate to any of this please tell me and we connect over this experience.Mommy Makeover Playlist: https://urlgeni.us/youtube/playlist/MMOplaylistCarnivore 1 Year Blood Work Results https://urlgeni.us/youtube/Carnivore1yearSemaglutide is the peptide in the name-brand Ozempic weight loss pen.Other GLP-1 are Liraglutide and Tirzepatide.SKIN & WELLNESS APP: ⁠https://urlgeni.us/AppInstall⁠NEWSLETTER ⁠https://urlgeni.us/NATURALKAOSNEWSLETTER⁠ASK IT any question you would ask me: ⁠https://mindos.com/share/265992794323804160⁠AMAZON LOCATIONSUS FACE SKINCARE ⁠https://www.amazon.com/shop/naturalkaos⁠CANADA FACE SKINCARE ⁠https://www.amazon.ca/shop/naturalkaos⁠UK FACE SKINCARE ⁠https://www.amazon.co.uk/shop/naturalkaos⁠SKINCARE SHOPSSHOP MY SHELF Products & Devices ⁠https://urlgeni.us/ShopMyShelf⁠ACID PEELS: ⁠https://www.makeupartistschoice.com⁠ KAOS20DR PEN USA CODE: KAOS15  ⁠https://drpen-usa.com⁠WHAT I USE TO CREATEMUSIC: Epidemic Sound ⁠https://www.epidemicsound.com/referral/qt9tsb/⁠FILMING EQUIPMENT: ⁠https://bit.ly/MyFilmingEquip⁠SOCIAL     MEDIAWEBSITE ⁠https://urlgeni.us/NKsiteAndblog⁠TIKTOK ⁠https://urlgeni.us/tiktok/NKskin⁠INSTAGRAM ⁠https://urlgeni.us/instagram/NKskin⁠FB PAGE ⁠https://urlgeni.us/facebook/NKFBpage⁠#weightlossjourney #ozempic #semaglutide #naturalkaos

As we work our way through the alphabet from A to Z in my drug pronunciation series, we're on the letter “L.” Disclaimer: we don't cover pharmacology in this series. Just drug names.   In this episode, I'll divide liraglutide, Victoza, and Saxenda into syllables, tell you which syllables to emphasize, and share my sources. Written pronunciations are helpful, so you'll find all three below and in the show notes for episode 324 on thepharmacistsvoice.com. Once you've listened to this episode, practice saying liraglutide, Victoza, and Saxenda. Repetition is the key to mastery.   Thank you for listening to episode 324 of The Pharmacist's Voice ® Podcast. The FULL show notes (including all links) are on https://www.thepharmacistsvoice.com/podcast.  Select episode 324.   Liraglutide = LIR a GLOO tide  LIR, like a Learjet Uh, which is a short “A” sound or a schwa “A” sound.  GLOO, like the sticky substance we use to stick two things together And tide, like the ocean tide Sources: Novo Nordisk Customer Service, MedlinePlus, and drugs.com    Victoza = VIC-tow-za  VIC, like Victor Tow, like a tow truck And za, like pizza Emphasize VIC Sources: Novo Nordisk Customer Service, drugs.com, and the FDA's website    Saxenda = sax en duh Sax, like a saxophone En, like the letter “N” in the alphabet Duh, which is an interjection we use in the US to mean, “Isn't it obvious?!” For example, if someone told you, “Water is wet,” you might say, “Duh! Water IS wet.”

Da diverso tempo l'uso di una specifica categoria di farmaci per indurre il dimagrimento è diventato motivo di dibattito. Sulla rivista  The Lancet in particolare, si sottolinea l'importanza della massa muscolare scheletrica nel contesto della perdita di peso indotta farmacologicamente, in particolare con l'uso diffuso di agonisti del recettore GLP-1. Questi farmaci, celebrati per la loro efficacia nel trattamento dell'obesità, hanno sollevato preoccupazioni riguardo una sostanziale perdita muscolare come parte del processo del calo di peso. 

On this podcast episode of the top 200 drugs, I'm covering liraglutide, folic acid, clotrimazole, empagliflozin, and semaglutide. Liraglutide is a GLP-1 agonist that can be used for weight loss as well as diabetes. The most common adverse effect of this medication is nausea. Folic acid is a commonly used supplement in pregnancy as well as in those patients taking methotrexate. Deficiency of folic acid can lead to anemia. Clotrimazole is an antifungal agent. It is mostly used for topical purposes such as athlete's foot and vaginal yeast infections. Empagliflozin was originally developed as a diabetes medication but can be helpful in patients with heart failure and CKD. I discuss this in greater detail in the podcast. Semaglutide is another GLP-1 agonist that is used for diabetes care as well as weight loss. The formulation used for diabetes is Ozempic while the weight loss product is Wegovy.

Dave brings you up to speed on the latest for all GLP-1 compounded medications. https://www.onthepen.com/post/zepound-and-mounjaro-shortage-judge-makes-shocking-move https://forum.policiesforpeople.com/t/compound-tirzepatide-and-semaglutide-transparency-in-fda-drug-shortage-process-503b-protection/7821 Decoding GLP-1: A Guide for Friends and Family of Those On The Pen By Dave Knapp

In this episode of Fat Science, Dr. Emily Cooper, Andrea Taylor and Mark Wright take a comprehensive look at the current FDA-approved medications designed to treat metabolic dysfunction and what may be approved next.  Dr. Cooper discusses the range of factors that determine whether these essential drugs are available for those who need them. Government approval, drug company strategies and insurance company policies all play a role.  Key Takeaways: Pharmaceutical Approval Process: Pharmaceutical companies typically seek FDA approval for one drug indication at a time due to the high costs and extensive trial requirements. Approval for obesity drugs is more stringent than for diabetes, involving costly and rigorous trials. Rebranding Drugs for Accessibility: Drugs like Liraglutide (originally Victoza for diabetes) are rebranded as Saxenda for obesity to bypass insurance coverage issues. However, rebranding can create coverage gaps for weight-loss purposes, leaving some patients without access. Insurance Coverage Challenges: Insurance companies often limit coverage for these medications unless a patient has a diagnosed condition like type 2 diabetes. Preventative benefits of metabolic medications are frequently overlooked by insurers, limiting broader access. Risks with Compounded Medications: Compounding pharmacies are creating untested versions of GLP-1 drugs to address affordability and shortages, raising safety concerns. Future Developments in Metabolic Meds: New potential drugs, such as a dual hormone agonist and high-dose semaglutide as a daily pill, show promise in improving metabolic health and accessibility. Resources: Connect with Dr. Emily Cooper on LinkedIn. Connect with Mark Wright on LinkedIn. Connect with Andrea Taylor on Instagram. Fat Science is a podcast on a mission to explain where our fat really comes from and why it won't go and stay away. We are committed to creating a world where people are empowered with accurate information about metabolism and recognize that fat isn't a failure. This podcast is for informational purposes only and is not intended to replace professional medical advice. If you have a question for Dr. Cooper, a show idea, feedback, or just want to connect, email us at info@diabesityinstitute.org. Fat Science is supported by the non-profit Diabesity Institute which is on a mission to increase access to effective, science-based medical care for those suffering from or at risk for diabesity. https://diabesityresearchfoundation.org/

Explore the big names in GLP-1s - Semaglutide, Liraglutide, and Tirzepatide - and learn how each one is shaping the weight loss landscape.   Jesse Frank https://www.lvrgfit.com jesse.dfrank@gmail.com   Charlie Seltzer https://drseltzerlifestylemedicine.com info@drseltzerweightloss.com

We're seeing a LOT more medications like Ozempic in the emergency department nowadays. In fact, 12% of U.S. adults have used a GLP-1 drug! So, what do we need to know about these drugs? Dr. Megan Boysen Osborn, Professor of Emergency Medicine at the University of California Irvine, discusses these GLP-1 agonists with host Maiya Smith.

TODAY ON THE ROBERT SCOTT BELL SHOW: Healthcare Consumerism vs. Patient Trust, Iron Overload and Liraglutide, Nutrition's Role in Medical Training, Psychological Bioterrorism Exposed, U.S. PR Campaign Against Pesticide Critics, Endocrine Disruptor Crisis, Hidden Dangers of Seed Oils, and MORE! https://robertscottbell.com/healthcare-consumerism-vs-patient-trust-iron-overload-and-liraglutide-nutritions-role-in-medical-training-psychological-bioterrorism-exposed-u-s-pr-campaign-against-pesticide-critics-e/

In this episode, we're diving deep into GLP-1 agonists, a topic that has sparked considerable debate within the fitness and health communities. Our special guest, Anthony Castor, brings a wealth of knowledge as the first non-physician to earn a fellowship with the Seed Scientific Research and Performance Institute. Together, we'll address controversies, debunk myths, and uncover the multi-faceted benefits of GLP-1 agonists far beyond their well-known role in weight loss and diabetes management. We'll explore their neuroprotective effects, benefits in managing neurodegenerative diseases like Alzheimer's and Parkinson's, and their surprising impact on cognitive decline, addiction, and ADHD. Moreover, we'll break down complex mechanisms, historical context, and real-world applications in an easily digestible format. Stay tuned as we demystify GLP-1 agonists and reveal how they can enhance not only physical but also mental resilience. Anthony Castor, a health advocate and educator, delves into the intricate world of peptides and their multifaceted benefits.   With a passion for making complex biochemical processes understandable, Anthony focuses on the potent impacts of GLP-1 (glucagon-like peptide-1), GIP (gastric inhibitory polypeptide), and myelin, among others. By demystifying how these peptides interact and function together, Anthony aims to shift public perception and drive forward significant improvements in health. Known for his use of analogies to clarify scientific concepts, Anthony is committed to educating people on the transformative potential of these sophisticated biochemical tools. Anthony's Website: https://www.castoremethod.com Instagram: https://www.instagram.com/anthonycastore/   Join Duffin Community & Education: https://www.skool.com/endless-evolution-8560/about www.chrisduffin.com

Suicidal ideation and GLP-1 agonists, a repeat of PARADIGM HF in Chagas CM, CASTLE HTx critical appraisal, and primary prevention of SCD in HF are the topics John Mandrola, MD, covers this week. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. Suicidal ideation with GLP-1 Signal of Suicidality With GLP-1 RA Semaglutide, but Experts Urge Caution https://www.medscape.com/viewarticle/signal-suicidality-glp-1-ra-semaglutide-experts-urge-caution-2024a1000fa7 Disproportionality Analysis from World Health Organization Data on Semaglutide, Liraglutide, and Suicidality   Variability in Disproportionality paper https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.668765/full II. PARACHUTE HF: Repeating the Mistakes in PARADIGM HF PARACHUTE HF https://www.jacc.org/doi/10.1016/j.jchf.2024.05.021 SOLVD https://www.nejm.org/doi/full/10.1056/NEJM199108013250501 CONSENSUS trial https://www.nejm.org/doi/full/10.1056/NEJM198706043162301 Meta-analysis of Low vs High Dose ACE/ARB https://doi.org/10.1161/CIRCHEARTFAILURE.117.003956 Meta-analysis of Sac/Val vs ARB/ACE Inhibitors https://link.springer.com/article/10.1007/s00228-024-03686-6 PARADISE MI https://www.nejm.org/doi/full/10.1056/NEJMoa2104508 III. CASTLE HTx Critical Appraisal Critical Appraisal of CASTLE HTx https://doi.org/10.1016/j.jacc.2024.06.020 CASTLE HTx https://www.nejm.org/doi/10.1056/NEJMoa2306037 CASTLE AF https://www.nejm.org/doi/full/10.1056/NEJMoa1707855 IV. More Data Suggesting Modest Benefits of the Primary Prevention ICD First and Recurrent ICD Shocks: JICE Paper from Denmark https://link.springer.com/article/10.1007/s10840-024-01873-0 HF trialists https://www.nejm.org/doi/full/10.1056/NEJMoa1609758 PROFID Trial https://profid-project.eu/ DANISH  https://www.nejm.org/doi/full/10.1056/NEJMoa1608029 SCD-HeFT https://www.nejm.org/doi/full/10.1056/NEJMoa043399 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Audio Commentary by Dr. Valentin Fuster, Emeritus Editor in Chief

It's In the News! A look at the top diabetes stories and headlines happening now. Top stories this week: The Eversense CGM could soon be approved for one year of continuous use, the first generic GLP-1 medication is launched, a new company tauts and all-in-one sensor and pump infusion set, a new diabetes accessory in the Roblox game, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX In the news is brought to you by Edgepark simplify your diabetes journey with Edgepark XX The first ever generic GLP-1 medication will soon be available in the US. It's a generic of Victoza, originally approved by the FDA in 2010 for diabetes, is part of the same class of drugs that includes Ozempic and Mounjaro. Liraglutide is Glucagon-like peptide-1 receptor agonists (otherwise known as GLP-1s or GLP-1 RAs) are a class of incretin drugs that mimic the body's natural hormones to help treat diabetes and obesity. However, the popularity of the drugs has spiraled out of control at times, leading to shortages and supply chain issues in the US and abroad.  The arrival of a GLP-1 generic drug provides reasons to be hopeful for doctors and patients alike, but there are also caveats. Couple of caveats - liraglutide is injected once daily (vs. weekly) and many doctors say it doesn't work as well for as many people as semaglutide and terzepatide. No confirmation on the price Two other generic options are being developed and could launch in December 2024. Patents for newer GLP-1 medications like Ozempic and Wegovy won't expire until several years down the road https://www.healthline.com/health-news/victoza-generic-glp1-drug-available XX Senseonics plans to launch a 365-day sensor in the U.S. in the fourth quarter of this year. A one-year Eversense CGM could be a game changer for the company.   In 2024, Senseonics expects to more than double U.S. new patient starts and increase the global installed base by around 50%. The growth is built on the current 180-day version of Senseonics' implantable Eversense CGM. Eversense's 180-day sensor can need calibrating twice a day, something Senseonics CEO Tim Goodnow said “has been a competitive disadvantage.” Users calibrate the 365-day sensor once a week. Senseonics is in talks with insulin pump manufacturers about integrating its Eversense CGM with their devices but has yet to commit to a timeline for finalizing an agreement. https://www.medtechdive.com/news/senseonics-365-day-cgm-2025-sales/719717/ XX People who take Ozempic or Wegovy may have a higher risk of developing a rare form of blindness, a new study suggests. Still, doctors say it shouldn't deter patients from using the medicines to treat diabetes or obesity.   Last summer, doctors at Mass Eye and Ear noticed an unusually high number of patients with non-arteritic anterior ischemic optic neuropathy, or NAION, a type of eye stroke that causes sudden, painless vision loss in one eye.   The condition is relatively rare — up to 10 out of 100,000 people in the general population may experience it — but the doctors noted three cases in one week, and each of those patients was taking semaglutide medications. The risk was found to be greatest within the first year of receiving a prescription for semaglutide.   The study, published Wednesday in the medical journal JAMA Ophthalmology, cannot prove that semaglutide medications cause NAION. And the small number of patients — an average of about 100 cases were identified each year — from one specialized medical center may not apply to a broader population. The ways that semaglutides interact with the eyes are not entirely understood. And the exact cause of NAION is not known either. The condition causes damage to the optic nerve, but there is often no warning before vision loss.   For now, patients who are taking semaglutide or considering treatment should discuss the risks and benefits with their doctors, especially those who have other known optic nerve problems such as glaucoma or preexisting visual loss, experts say https://www.reuters.com/business/healthcare-pharmaceuticals/wegovy-ozempic-linked-with-sight-threatening-eye-disorder-study-2024-07-03/ XX We got some updates at ADA about the over the counter CGMS Dexcom Stelo and Abbot's Libre. Dexom plans a late august launch of stelo, which you'll order from their website – it won't be physically in stores. Abbott also plans to sell its wellness-oriented Lingo device this summer through an e-commerce website. That's a sensor that's been available in other coutnires for a while, but was recently okayed in the US. It's not meant for people with diabetes. The Libre Rio is designed or adulst with type 2 who don't use insulin. No timing yet on that product's launch. Neither Abbott nor Dexcom have disclosed pricing for the upcoming products. https://www.medtechdive.com/news/abbott-dexcom-over-the-counter-cgm-launch/719928/ XX Insulet is looking to expand the label for its Omnipod 5 insulin pump for people with Type 2 diabetes. The company said Friday it recently filed with the Food and Drug Administration. Insulet presented study results at the American Diabetes Association's 84th Scientific Sessions that evaluated Omnipod 5 in people with Type 2 diabetes who were taking basal insulin or multiple daily injections. The results showed “substantial improvements in blood glucose outcomes and overall quality of life,” said study chair Francisco Pasquel, an associate professor of endocrinology at Emory School of Medicine. Omnipod 5 is currently cleared in the U.S. for people with Type 1 diabetes. Insulet hopes to expand the pump to people with Type 2 diabetes, with an expected launch in early 2025. The FDA has not yet cleared any automated insulin delivery systems for people with Type 2 diabetes, Insulet said. The company has a basal-only insulin pump, called Omnipod Go, that was cleared for people with Type 2 diabetes last year, but it does not connect to other devices. Even though Omnipod 5 is not currently indicated for Type 2 diabetes, doctors prescribe it for their patients with full reimbursement since the pharmacy channel doesn't distinguish between Type 1 or Type 2 patients, J.P. Morgan analyst Robbie Marcus wrote in a research note on Sunday. https://www.medtechdive.com/news/insulet-omnipod-5-type-2-diabetes-study/719644/ XX In the keynote address at the American Diabetes Association annual conference, FDA Commissioner Dr. Robert Califf expressed concerns about the rising rates of diabetes in the U.S. Though revolutionary medications and technologies for diabetes and weight loss continue to emerge, these treatments are vastly underused. The silver lining lies with type 1 diabetes therapies, which are showing great promise in clinical trials. “For the larger epidemic of type 2 diabetes, we're failing right now,” Califf said. “I don't say that lightly.” A huge problem, Califf said, is access. While most health insurance plans cover medical devices and medications for diabetes, without insurance, costs add up quickly. Ozempic, for example, costs nearly $1,000 per month without insurance. Studies have found that regardless of insurance status, roughly 26% of Americans skipped or delayed treatment due to cost. https://diatribe.org/diabetes-management/fda-commissioner-says-were-failing-people-type-2-diabetes XX Embecta presented two abstracts at the American Diabetes Association Scientific Sessions last weekend making the case for its insulin patch pump for Type 2 diabetes. The company submitted the device for Food and Drug Administration clearance in late 2023. The diabetes device company developed a patch pump with a larger insulin reservoir that can hold up to 300 units. Embecta, which is better known for making equipment such as pen needles and insulin syringes, has been developing its first patch pump. The company found that a device with a larger insulin reservoir could provide longer wear times and fewer disposable patches. https://www.medtechdive.com/news/embecta-insulin-patch-pump-volume-american-diabetes-association/719779/ XX   Pump/CGM sensor in one The niaa signature patch pump, shown with a watch displaying current blood sugar level The niaa signature patch pump has a manual bolus button and is part of an in-development AID system. Swiss technology maker Pharmasens demonstrated a new semi-reusable tubeless patch pump and glucose sensor in the same compact device, called the niia signature, which the company says can be worn for five days.   The top of the device, which includes Bluetooth connectivity and the electronic and mechanical parts to control the pump, separates from the disposable 300-unit reservoir along with the adhesive used to attach the device to the body via a steel cannula. A small button on the device allows manual bolusing. The company says an AID system will manage the device, controlled by smartphone.   PharmaSens' simpler basal-bolus patch pump, the niia essential, was submitted for FDA approval in late December. Availability of the niia signature AID system has yet to be announced. https://diatribe.org/diabetes-technology/diabetes-technology-display-ada-2024 XX Edgepark Commercial XX New international consensus statement offers guidance on the care and monitoring of people who are at high risk for type 1 diabetes (T1D). This is all about screening and testing for islet autoantibodies. These individuals are classified as: At risk or Stage 0 (single autoantibody or transient single autoantibody), Stage 1 (two or more autoantibodies with normoglycemia), and Stage 2 (two or more autoantibodies with dysglycemia but without symptoms and not yet meeting diagnostic criteria for Stage 3 clinical T1D). The document was presented on June 24, 2024 in a 90-minute symposium at the American Diabetes Association's annual Scientific Sessions and published simultaneously in both Diabetes Care and Diabetologia. "This is not guidance around who to screen or when to screen. This is guidance for the hundreds of thousands of people around the world who have participated in screening, mostly through research programs, and have been identified with positive autoantibodies and need care in the clinical setting," panel co-chair Anastasia Albanese-O'Neill, PhD, APRN, CDCES, of Breakthrough T1D, told Medscape Medical News.   The recommendations also include when to start insulin, and how to provide education and psychosocial support to individuals and family members of those given the early-stage T1D diagnosis. https://www.medscape.com/viewarticle/experts-advise-early-risk-monitoring-type-1-diabetes-2024a1000bpo XX Roblox has added a diabetic option, complete with insuli pen and Dexcom You can find it in the marketplace JDRF – now breakthrough t1d – started a world in roblox a couple of years ago as well Roblox is a super popular online game that a lot of kids play. https://www.roblox.com/games/5823990610/Breakthrough-T1D-World XX FFL next week! Join us again soon!

How many patients maintain weight loss 1 year after discontinuing semaglutide or liraglutide? Find out about this and more in today's PeerDirect Medical News Podcast.

A class of medications known as GLP-1 receptor agonists has revolutionized the treatment of type 2 diabetes and obesity. These drugs mimic the action of glucagon-like peptide-1 (GLP-1), a hormone that stimulates insulin secretion and inhibits glucagon release, helping to regulate blood sugar levels and promote weight loss. In this podcast, we'll talk about the differences among some of the most well-known GLP-1 receptor agonists for type 2 diabetes. Ozempic (Semaglutide) Form: Injectable Dosing Frequency: Once weekly Uses: Primarily for type 2 diabetes (lower blood sugar and A1c); also approved for reducing the risk of major cardiovascular events like heart attack and stroke in adults with type 2 diabetes and known heart disease. Keep in mind, Wegovy (semaglutide) is a higher-dose version that's approved for weight loss. When you start taking Wegovy or Ozempic, you'll begin with a low dosage. Your prescriber will increase your dosage every four weeks until you reach the target amount. However, the specific dosage you inject will differ depending on the medication. The maximum dose for Ozempic is 2mg weekly, while the target dose for Wegovy is 2.4mg weekly. Rybelsus (Semaglutide) Form: Oral tablet Dosing Frequency: Once daily Uses: Lower blood sugar and A1c in people with type 2 diabetes. Rybelsus shares the same active ingredient as the injectable medications Ozempic and Wegovy. Ozempic is also approved for Type 2 diabetes, while Wegovy is approved specifically for weight loss. Rybelsus is available in three different strengths: 3 mg, 7 mg, and 14 mg. Similar to Ozempic, the dose is slowly increased every 4 weeks.  Good to know: It's important to take Rybelsus first thing in the morning with 4 oz of water. After taking it, you should wait at least 30 minutes before eating, drinking, or taking other medications. Failing to do so may reduce its effectiveness. Currently, Rybelsus is undergoing clinical trials to evaluate its effectiveness for weight loss. The trials involve higher doses than those approved for diabetes treatment. Results indicate that a 50 mg dose of oral semaglutide (Rybelsus) achieves weight loss comparable to Wegovy.  Trulicity (Dulaglutide) Form: Injectable Dosing Frequency: Once weekly Uses: Type 2 diabetes; and like Ozempic, it's also approved for reducing the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. Like Ozempic and Rybelsus, you will start at a low dose to help reduce side effects. Your healthcare provider will then gradually increase the dose, balancing the management of side effects with the benefits of blood sugar control. The maximum dose for Trulicity is 4.5mg weekly. Victoza (Liraglutide) Form: Injectable Dosing Frequency: Once daily Uses: Type 2 diabetes; also approved to reduce the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. Victoza is one of three GLP-1 agonists approved for treating Type 2 diabetes in children aged 10 and older. The other options are Trulicity (dulaglutide) and Bydureon BCise (exenatide). More on this later. Ozempic, however, is only approved for use in adults. Saxenda and Victoza are both injectable medications containing liraglutide, but they are approved for different uses. Saxenda is FDA-approved for chronic weight management in people 12 and older, while Victoza is approved for treating Type 2 diabetes in people 10 and older. Victoza also helps lower the risk of major adverse cardiovascular events in adults with diabetes and heart disease. Both medications are injected once a day, starting with a low dose that is gradually increased over time. The target dose for Saxenda is 3 mg once daily, whereas the maximum dose for Victoza is 1.8 mg once daily. Byetta (Exenatide) Form: Injectable Dosing Frequency: Twice daily Uses: Type 2 diabetes. Additional Benefits: It has a shorter duration of action than other GLP-1 agonists, which may be preferable for some patients. Byetta, approved in 2005, was the first GLP-1 medication of its kind for diabetes. Its active ingredient, exenatide, is a synthetic version of a substance found in Gila monster saliva.  The recommended starting dose for Byetta is 5 mcg twice daily, administered within 60 minutes before your morning and evening meals. After one month, your healthcare provider may increase the dose to 10 mcg twice daily. Starting at a lower dose helps reduce stomach-related side effects. Bydureon BCise (Exenatide Extended-Release) Form: Injectable Dosing Frequency: Once weekly Uses: Type 2 diabetes. Additional Benefits: Extended-release formulation provides a more convenient dosing schedule compared to Byetta. Unlike Byetta, Bydureon BCise has a fixed dose of 2 mg administered once weekly, on the same day each week. It can be taken at any time of day, with or without food. Mounjaro (Tirzepatide) Form: Injectable Dosing Frequency: Once weekly Uses: Type 2 diabetes. Additional Benefits: Dual action as it targets both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, potentially offering enhanced efficacy in blood sugar control. Mounjaro is not approved for weight loss; however, its active ingredient, tirzepatide, is approved for weight loss under the brand name Zepbound. Typically, Mounjaro's starting dose is 2.5 mg once weekly for four weeks. By week 5, the dosage is often increased to 5 mg once weekly for another four weeks. Following week 9, if necessary for better blood sugar management, the dosage can be escalated to 7.5 mg weekly. It's important not to increase Mounjaro doses by more than 2.5 mg every four weeks. The maximum recommended dosage is 15 mg once weekly. Unlike Ozempic, Trulicity, or Victoza, Mounjaro is currently not approved for any heart-related uses. However, an ongoing clinical trial is assessing its effectiveness in reducing major adverse cardiovascular events in people with Type 2 diabetes. The study is anticipated to conclude in October 2024. Key Differences and Considerations The right GLP-1 agonist for you will likely come down to a few key factors like age, treatment goals, and underlying health conditions. Personal preferences like dosage frequency will also come into play. Dosing Frequency: Once weekly: Ozempic, Trulicity, Bydureon BCise, Mounjaro. Once daily: Rybelsus (oral), Victoza, Saxenda. Twice daily: Byetta. Administration Form: Injectable: All except Rybelsus (oral). Oral: Rybelsus. Indications: Type 2 Diabetes: All medications. Cardiovascular Benefits: Proven cardiovascular benefits: Ozempic, Trulicity, Victoza. Pediatric Use: Approved for children: Victoza (for children 10 years and older). Thanks again for listening to The Peptide Podcast. We love having you as part of our community. If you love this podcast, please share it with your friends and family on social media, and have a happy, healthy week! We're huge advocates of elevating your health game with nutrition, supplements, and vitamins. Whether it's a daily boost or targeted support, we trust and use Momentous products to supercharge our wellness journey.  Momentous only uses the highest-quality ingredients, and every single product is rigorously tested by independent third parties to ensure their products deliver on their promise to bring you the best supplements on the market. 

Is there potential for recovery in patients who are withdrawn from life support? Find out about this and more in today's PeerDirect Medical News Podcast.

Join me with Dr. Damon McCune as we dive into the hot topic of Ozempic and its impact on the world of weight management. We explore not just Ozempic, but other groundbreaking weight loss drugs, discussing their potential, efficacy, and what bariatric patients specifically need to consider. Tune in to uncover the latest advancements in medical treatments for obesity and learn how these innovations can be part of a comprehensive approach to health and weight loss. Need Support ? www.theritelife.com support@theritelife.com

Two articles in the March-April 2024 issue of the Journal of Clinical Psychopharmacology present research on glucagon-like peptide-1 receptor agonists (GLP-1 RAs),  a class of medications that has drawn considerable media attention in recent months for their ability to promote significant weight loss. The articles in JCP consider their use in specific populations of patients: individuals with bipolar disorder or eating disorders (in this case, atypical anorexia nervosa). This podcast features a discussion of the articles by authors Susan L. McElroy, MD; Anna Ward, ARPN; and Dr. Anna Guerdjikova, PhD, LISW, from the Lindner Center of HOPE in Mason, OH, and the University of Cincinnati. The first article, Liraglutide in Obese or Overweight Individuals With Stable Bipolar Disorder, reports on a placebo-controlled double-blind trial, which showed that compared with placebo, liraglutide was associated with greater reductions in percent change in body weight, and reductions in weight, body mass index, binge eating and hunger. Obesity is common among individuals with bipolar disorder, possibly contributing to their well-documented higher risk of cardiovascular-related mortality. The second article is titled Semaglutide Misuse in Atypical Anorexia Nervosa – A Case Report. The report presents the case of a patient with a history of an eating disorder who intentionally misused the GLP-1 semaglutide and lost more than 40  pounds in 9 months. The case report is designed to alert clinicians of the importance of reviewing patients' medical and psychiatric histories, being attuned to patient histories of weight fluctuations, and screening for eating dysregulation when prescribing weight-loss approved medications.

In this episode of The Atlas Podcast, we dive into the world of weight management and body optimization with Kelley Wright, MD, and IFBB Bikini Pro. With her 25 years of medical experience, Dr. Wright illuminates the science and myths about Semaglutide, Liraglutide, Ozempic, and Wegovy. We share personal stories, discuss the effects of hormones like leptin and ghrelin, highlight the true benefits, and clear up myths, such as muscle loss and 'Ozempic face.' Furthermore, Dr. Wright offers insights into the specific challenges bodybuilders face, from reading bloodwork and managing liver enzymes to balancing hormones. The conversation also covers PEDs, female fertility, TRT, gut health, and optimizing sleep. This episode is perfect for anyone eager to bridge the gap between medical science and competing as an athlete. The Atlas Podcast is available on: YouTube: bit.ly/AtlasPodcastYoutubeSpotify: bit.ly/AtlasPodcastSpotifyApple Podcast: bit.ly/AtlasPodcastAppleGoogle Podcast: bit.ly/AtlasPodcastGoogle Stay Connected: @navydoc_ifbbpro @413medicalaesthetics Discount links: https://linktr.ee/Jamesayotte Team Atlas Website: www.teamatlasfitness.com James Ayotte's Website: www.jamesayotte.com Team Atlas on Instagram: @teamatlasmtl & @teamatlaslifestyle James on Facebook: https://www.facebook.com/james.ayotte.79 James on Instagram: @jamesxatlas Atlas Podcast on Instagram: @atlaspodcastx

In this episode, Jennifer Green, MD, and Carol Hatch Wysham, MD, break down the latest headlines on incretin-based therapies and how to address these topics with patients. Their discussion includes:Beneficial effects beyond glycemic control Adverse events and how to manage themNon- or partial responders and the importance of setting expectations with patients Weight rebound when discontinuing therapyMedication access issues related to cost and drug availability Presenters:Jennifer Green, MDProfessor of MedicineDivision of Endocrinology and Duke Clinical Research InstituteDuke University School of MedicineDurham, North CarolinaCarol Hatch Wysham, MDClinical Professor of MedicineClinical EndocrinologistMultiCare/Rockwood ClinicSpokane, WashingtonLink to online program: https://bit.ly/48b6XnW

Beginning with a discussion on the evolution of these medications, Dr. Bikman emphasizes their significance in combating obesity-related health issues. He proceeds to analyze the mechanisms of popular weight loss drugs, such as Orlistat, Phentermine, and the combination of Phentermine with Topiramate, elucidating how each functions to aid weight loss.While highlighting the benefits, Dr. Bikman doesn't shy away from detailing the potential side effects, ensuring a comprehensive understanding for the audience. Moreover, he shares an intriguing scientific fact regarding lactate's role in fat metabolism, adding depth to the discussion. Throughout, Dr. Bikman maintains a balance between scientific evidence and personal insight, fostering an engaging and informative session.In discussing liraglutide's mechanism of action, Dr. Bikman reveals its role as a GLP-1 receptor agonist, mimicking the actions of the incretin GLP-1. He then previews next week's class dedicated to incretins and their use in weight loss drugs, including medications like wegovy and ozempic.Liraglutide primarily promotes weight loss by reducing gastric emptying, leading to prolonged feelings of fullness and decreased appetite. Additionally, it inhibits glucagon, lowering blood glucose levels and subsequently increasing metabolic rate and fat burning. Dr. Bikman notes common side effects such as gastrointestinal discomfort and hints at potential risks of thyroid tumors associated with GLP-1 agonists.Ben transitions to discussing semaglutide, another GLP-1 receptor agonist, and its similar effects on weight loss and side effects, including the possibility of ileus. He also touches on metformin's off-label use for weight loss, its mechanisms involving AMPK activation and ATP inhibition, and its potential interference with exercise-induced mitochondrial benefits.Learn more at: Insulin IQ Hosted on Acast. See acast.com/privacy for more information.

Dr. Ellen Csepe // #ClinicalTuesday // www.ptonice.com  In today's episode of the PT on ICE Daily Show, MMOA faculty member Ellen Csepe discusses this new class of medicines and how they impact your patients and their overall journeys to maximize their fitness and manage their weight. Take a listen or check out the full show notes on our blog at www.ptonice.com/blog. If you're looking to learn more about live courses designed to better serve older adults in physical therapy or our online physical therapy courses, check our entire list of continuing education courses for physical therapy including our physical therapy certifications by checking out our website. Don't forget about all of our FREE eBooks, prebuilt workshops, free CEUs, and other physical therapy continuing education on our Resources tab. EPISODE TRANSCRIPTION INTRODUCTION Hey everyone, this is Alan. Chief Operating Officer here at ICE. Before we get started with today's episode, I want to talk to you about VersaLifts. Today's episode is brought to you by VersaLifts. Best known for their heel lift shoe inserts, VersaLifts has been a leading innovator in bringing simple but highly effective rehab tools to the market. If you have clients with stiff ankles, Achilles tendinopathy, or basic skeletal structure limitations keeping them from squatting with proper form and good depth, a little heel lift can make a huge difference. VersaLifts heel lifts are available in three different sizes and all of them add an additional half inch of h drop to any training shoe, helping athletes squat deeper with better form. Visit www.vlifts.com/icephysio or click the link in today's show notes to get your VersaLifts today. ELLEN CSEPEHey, good morning everybody. And welcome to the PT on ICE daily show brought to you by the coolest continuing education company in all of healthcare. My name is Ellen Csepe. I'm coming to you live from Littleton, Colorado. I normally teach with the older adult division, but today we're going to be talking about GLP one agonist medications and their impact on your patients. Um, You guys have probably heard about GLP-1 medications. They're all over social media right now. They're used to manage obesity and weight issues um and diabetes, so These medications are the medicines like ozempic that you've heard all about or the medication brand of that same Ozempic, but used for obesity, which is called Wegovy. So you've probably heard a lot about these medicines already. And if you didn't see them on your board questions, you might be feeling a little bit out of the loop as to how they could impact your patients. If you're like me, these medications have come out after I've already gotten my licensure as a PT, and these medicines are impacting our patients in ways that I'm not really familiar with. So, this podcast episode today is for you to know a little bit more about how these medicines could be impacting your patients as a rehab professional. This podcast is going to be a lot about introductory level information to talk about these medicines in context of our Patients with obesity this podcast is not going to be a conversation to talk about How these medicines are used by celebrities they're not going to be we're not going to talk about how these compound medications or Illegal versions of these medicines are flooding our healthcare scene and causing a lot of illnesses today, we're gonna be really talking about what they are and how they work, who they're for, what they do other than help people lose weight, and some considerations and practical tips for your patients. GLP-1 MEDICATION So let's talk a little bit more about how these medicines work. So in context of treating obesity, these GLP-1 medications are super helpful to kind of overcome the biology behind our body's resistance to losing weight. Let me break that down a little bit. I know it's really easy to look at somebody with weight issues and think, gosh, wouldn't they just feel better if they lost weight? And it's an interesting paradox because our bodies actually fight to regain lost weight. Our bodies might feel better. We might have less pain, less inflammation, less joint problems, but Unfortunately, when we lose a substantial amount of weight, our body's biology fights to regain that. Why? Because usually in the context of our human existence, losing weight has always been a bad thing and it usually means being in starvation. Unfortunately, our biology doesn't know that obesity can be just as much of a threat to our health as starvation. So, when our weight changes, unfortunately our ghrelin or the hormone circulating in our blood blood that's Tells us we're hungry unfortunately that increases when we've lost weight and unfortunately leptin or that satiety hormone is decreases when we lose weight. What does that mean for our patients? It means that losing weight is very difficult to maintain because our body is constantly fighting to get that weight back. So let's talk about these GLP-1 medications. I'd like to first start out by saying GLP-1 medications are the newest medications that are used to treat obesity, but they're not the only ones. They just have a lot fewer side effects than some of the other medications that we've used in the past. For example, oralistat is a medication that works at our gut to decrease the absorption of fat. It comes with a ton of really gnarly side effects. Google what steatorrhea is, and you'll see what I mean. Unfortunately, there are tons of GI side effects for people that use this medication that cause significant fat in their stools and a lot of loose stools with it. Another medication is fentramine or topiramate. Those medications used in combination Basically act as a sympathomimetic to increase our metabolism But those medications are really only effective for a short period of time and they can have a lot of cardiac side effects There are some medications that are used in combination to treat obesity specifically naltrexone was a medication to use to treat opioid addiction and bupropion is which is another antidepressant, in combination that kind of changes our satisfaction behind eating. Those are medications used to treat obesity too. And usually what we can guess is that those medications aren't going to be quite as effective as GLP-1 medicines. Just to kind of review if you're tuning in now, those GLP-1 medications are medications like Wegovy, Sexenda, Ozempic, although of note, Ozempic is only used to treat obesity as an off-label benefit. Ozempic is actually only, excuse me, only approved to treat diabetes by the FDA right now. MECHANISMS OF GLP-1 MEDICATION So let's talk a little bit more about what this GLP medication is. GLP-1 is a hormone that we naturally secrete in our bodies. and the GLP-1 medicines are receptor agonists that look pretty similar to that hormone in our bodies and that when used mimic that hormones actions throughout our tissues. For example at the pancreas that GLP-1 receptor increases our body's secretion of insulin and helps to make that insulin last better. So that's why it's also used for people with diabetes. Interestingly enough, we also have GLP-1 receptors in our stomach. So another way this medicine works is to slow gastric emptying and basically make our food last longer throughout our stomachs so that we feel fuller for longer. What I think is the most interesting is that we have these GLP-1 receptors in our brain, in our hypothalamus, and the way these GLP-1 medicines work is to suppress both hunger and cravings. A lot of people with obesity experience something called food noise. And basically because of the obesity, they have these constant and intrusive thoughts about food. They could be eating something and have no hunger, but already be thinking about their next meal. So this GLP-1 agonists, Turn down that food noise to make it less likely for them to experience these constant intrusive thoughts about hunger So we talked a little bit about how they work. Let's talk a little bit more about who they're for so GLP-1 agonists are used for people with obesity. So that means generally their BMI is 30 or more or they could have overweight and a BMI of 27 with comorbidities. Comorbidities specific to their weight significantly causing risks to their health. So these medications aren't just for people who are looking to shed a few pounds. Obesity is a disease and these medicines really help us treat that disease process, which is a long-term, lifelong problem that relapses and recurs, unfortunately, in a lot of patients. It's contraindicated in a few patients. Good news, patients' physicians have to figure that out, not us. But just for context, people that are pregnant, people that have gastroparesis, irritable bowel disease, those patients might not be appropriate for these medicines, as well as those with certain thyroid cancers or familial risks of those cancers. So these medicines are also used to treat diabetes and in patients with obesity and diabetes, this is a great new medication to manage both conditions at once. Interestingly, or Wigovy, which is the ozempic for obesity, is also used to treat those who are 12 and older. So it's not just adults that are using these medicines, it's also those with obesity who are children who are 12 or older and weigh 132 pounds or more and have obesity. So let's talk a little bit about what they do. So pragmatically, they really reduce cravings. We talked about that. They can result in about an 8 to 15 percent weight loss in the first year of use. That's a lot compared to some of the older classes of medication. Liraglutide decreases the risk of diabetes compared to a placebo. So in those with obesity, liraglutide decreases the risk of obesity development and that rate of onset much sooner. So these aren't just to lose a few pounds before summer and celebrities. This medication can be very helpful for people who are struggling with their weight long term. Notably, Long term is how long these medications have to be used. So unfortunately, in most users, if they discontinue this medication, weight is almost always regained, and about 66% of the weight that they've lost over the past year is regained when people stop using this medication. but again, this isn't just a cosmetic thing to lose weight and a lot of us as Providers think about weight in the context of how we look societally and how we feel but this medication in those with obesity and diabetes Decreases the risk of cardiovascular events decreases the risk of stroke atherosclerosis Heart attack. So these medications aren't just here to help you get shed a few pounds These can be really life-saving medications for those with obesity CLINICAL CONSIDERATIONS Let's kind of talk through some of the considerations for you as a clinician. So keep in mind these medications are injected by the patient at home one time a week. And the dose is gradually increased to a therapeutic dose over several months. Here's why that matters. Because there are quite a few side effects with these medications. It's not a medicine that comes without side effects. This is not the easy way out to lose medicine. It does not feel good to be on these medicines. And a lot of the most common side effects are going to be nausea, vomiting, GI issues, cramping, bloating, dizziness, headaches and fatigue, hypoglycemia, which is important for us to consider for our patients if we're going to be having them exercising, acute pancreatitis, and gallbladder disease. So how does that impact our patients? Friends, team, we are in the business of helping our patients maintain their muscle mass. That's our job. Our job is to be fitness forward, to advocate for our patients, and to be here for them through every season of life. And on the days that they're taking these medicines and throughout the week, there's a lot of stigma attached to these medicines that we have to be aware of as providers. Where I'm going with that is that they need a hype squad. Patients need somebody to cheer them on and say hey, I know you feel like crap. I know that this medication is hard What I want you to know is that I'm here in your corner You are making a big decision for your health and even if you only lose five to ten percent of your weight Overall, that is a huge huge way to reduce your risk of overall cardiovascular disease. HYPE UP YOUR PATIENTS So friends We need to hype up our patients who are on these medicines when it's appropriate and it usually is if it's prescribed by a doctor. This needs to be our goal to hype up our patients and encourage them to maintain their consistency with this medicine. A lot of patients stop because they plateau losing weight after about a year. And they still have the side effects. So they feel like crap. They don't want to take this medicine. They're not seeing the pounds shed off anymore. And they need a health care provider to say, hey, this isn't just a quick fix to lose a few pounds. This is a lifelong endeavor to manage obesity, which has serious risks to your health. So another consideration, our business is to make sure that our patients are sticking through these medicines and Also maintaining their exercise participation and their muscle mass So patients who are taking these medicines feel like crap. They need somebody to still say hey I know you don't feel great. We still need to have a plan to have you doing strength training. We still need to have a plan for you to get enough protein in your, in your, in your mouth throughout the day, because unfortunately these medicines work by saying, Hey, you're not so hungry anymore, which is how those medicines are effective. But unfortunately, if you're not intentional, you will lose not only fat mass, but muscle mass with this endeavor with using these medicines. So, Encouraging your patient. Hey, I know you're losing weight. This is awesome Let's really keep this ball rolling and be super Intentional to make sure that you're still able to get to the gym that you're still able to get enough protein in your diet I'm on your team. I am in your corner to help you and These patients are prime time for behavioral change to say i'm making a change on myself already with this medicine. How can I really? Maximize this and get as much as I can and we are on their team team I recommend patients to talk with their doctor about these medicines. I talk with my patients about their weight all the time in a way that's constructive and empathetic. I listen to my patients and recognize that losing weight is a struggle. These medicines can be super helpful for our patients who have struggled for a long time to manage their weight. And that's not because they're unmotivated or lazy, it's because their biology is fighting to get that weight back. This is not cheating and these medications can be super helpful. I often talk with patients and recommend them to go back to their doctors and ask if it could be helpful in their journey to manage their weight. A quick caveat on that, not all insurances in all states cover these medicines the same, which is very unfair. These medications can be really life-saving for our patients with obesity, and unfortunately, insurance is making it hard for people that need it most to get access to it, specifically those in poverty. Obesity disproportionately affects those from a lower socioeconomic status, and it's really important to recognize that in the treatment of obesity, those people are unfortunately going to be the last to get access to this stuff, and that stinks. So knowing that as a provider is another important thing that I've learned. You can't just shoot from the hip and say, oh, you've got to go talk to your doctor about this. It might not be covered by their insurance, and that's super demoralizing. So make sure that you kind of know that before you make this recommendation that, oh, you can be on this new drug, it'll be super helpful for you, and it's not covered. So friends, to wrap up this summary, so these GLP-1 medications are new but not the only way that obesity can be treated medically. They're very helpful and effective in helping those individuals lose weight but they often come with side effects. Our job as providers is to know what those side effects look like and feel like and how to still emphasize exercise participation to our patients no matter how they feel and come up with a plan to say, hey, we still need to do strength training. We still have protein goals to make sure that you maintain your muscle mass. Thank you guys so much for taking time out of your morning to join me to talk about these medicines. And I hope that it was helpful in the long run for you to know how they can be helpful for your patients. Have a great day. OUTRO Hey, thanks for tuning in to the PT on ICE daily show. If you enjoyed this content, head on over to iTunes and leave us a review, and be sure to check us out on Facebook and Instagram at the Institute of Clinical Excellence. If you're interested in getting plugged into more ice content on a weekly basis while earning CEUs from home, check out our virtual ice online mentorship program at ptonice.com. While you're there, sign up for our Hump Day Hustling newsletter for a free email every Wednesday morning with our top five research articles and social media posts that we think are worth reading. Head over to ptonice.com and scroll to the bottom of the page to sign up.

Today On Medical Grounds, we will be speaking with Dr. Heather Whitley. Dr. Whitley is a clinical professor in the Department of Pharmacy Practice at the Auburn University Harrison College of Pharmacy. She is a board certified pharmacotherapy specialist and a certified diabetes educator. Earlier this year, Dr. Whitley spoke with us about screening for diabetes in high-risk individuals. Today, she is back to talk about some new things going on in the diabetes and pharmacy world. This is part 1 of a two part series. In Part 1, Dr. Whitley will be discussing shortages in GLP-1 agonist drugs for diabetes and what pharmacists can do to address those shortages.Dr. Whitley recently published a paper in Clinical Diabetes about this topic:Special Report: Potential Strategies for Addressing GLP-1 and Dual GLP-1/GIP Receptor Agonist Shortages(00:09) Introduction to Dr. Whitley(01:08) Publication on strategies for GLP-1 and GLP-1/GIP shortages(02:36) GLP-1 and GLP-1/GIP agonists, names, and dosing(04:15) Why are there shortages?(08:52) Alternatives(10:11) What happens if a patient misses a dose?(12:19) Re-initiation of medications(14:51) GLP-1 agonist equivalency(15:31) Substituting SGLT2s(17:16) Self-sourcing or online sourcing problems(21:51) Managing patient expectations and concernsVisit us at OnMedicalGrounds.com for more podcasts! You can subscribe through your podcast platform, our website, or follow us on social media for podcast updates and medical news. Some of our podcasts offer FREE CME/CE credits.LinkTreeTwitterLinkedInInstagram

GLP1 agonist weight loss medications Wegovy and Ozempic have become popular medications for overweight and obesity and are also increasingly being used in psychiatry to target symptoms of depression and anxiety. But are Wegovy and Ozempic safe to use in psychiatry? University of Toronto psychiatrist and researcher Dr. Rodrigo Mansur discusses the research supporting the use of GLP1 agonist weight loss drugs and explores his clinical considerations when discussing these medications with patients. Could they be a new treatment for psychiatric disorders? That remains to be seen as we consider the potential adverse effects. But it seems clear these drugs are becoming more popular, so the more we know about them, the better! Expert featured in this episode: Rodrigo Mansur MD PhD https://psychiatry.utoronto.ca/faculty/rodrigo-mansur Dr. Mansur's publication mentioned in this video: Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: A pilot, open-label study https://pubmed.ncbi.nlm.nih.gov/27721184/ About us: Metabolic Mind™ is a nonprofit initiative incubated by Baszucki Group. Our mission is to provide education and resources in the emerging field of metabolic psychiatry, including ketogenic interventions for mental disorders. Our channel is for informational purposes only. We are not providing individual or group medical or healthcare advice nor establishing a provider-patient relationship. Many of the interventions we discuss can have dramatic or potentially dangerous effects if done without proper supervision. Consult your healthcare provider before changing your lifestyle or medications. #MetabolicMind #KetoForMentalHealth #MetabolicPsychiatry #BipolarTreatment #KetogenicMetabolicTherapy #NutritionalKetosis#MentalIllness#Bipolar#GLP1#Ozempic#Wegovy#Weightloss

What does the body of evidence say on Ozempic and its impact on diabetes and obesity? Plus: can you trade in your antidepressant for a jog, and Chris returns to the hot seat to diagnose a teenage boy who fell during a baseball game! Block 1: (2:22) Ozempic/Wegovy: GLP-1 receptor agonists; the difference between them; Mounjaro; Trulicity; diabetes biology; glucagon-like peptides 1 and 2; the problem with GLP-1; DPP4 inhibitors Block 2: (12:33) Ozempic/Wegovy: The venom of the Gila monster; how semaglutide became a blockbuster drug; weight loss; the numerous clinical trials; the impact on the stock prices of dialysis companies; downsides; the Internet craze Block 3: (27:03) Is running as beneficial for depression as medication? Block 4: (36:42) The case of the baseball player's heart   * Jingle by Joseph Hackl * Theme music: “Fall of the Ocean Queen“ by Joseph Hackl * Assistant researcher: Aigul Zaripova   To contribute to The Body of Evidence, go to our Patreon page at: http://www.patreon.com/thebodyofevidence/. To make a one-time donation to our show, you can now use PayPal! https://www.paypal.com/donate?hosted_button_id=9QZET78JZWCZE Patrons get a bonus show on Patreon called “Digressions”! Check it out!   References: 1) History of GLP-1 receptor agonists: https://www.statnews.com/2023/09/30/weight-loss-ozempic-nobel-prize-science/ 2) Liraglutide vs. exenatide: https://doi.org/10.1016/S0140-6736(12)61267-7 3) Meta-analysis of GLP-1 receptor agonists: https://doi.org/10.1111/dom.12849 4) A brief summary of the SUSTAIN studies, all 11 of them, which demonstrated the efficacy of semaglutide and its cardiovascular benefit: https://diabetes.medicinematters.com/semaglutide/type-2-diabetes/a-quick-guide-to-the-sustain-trials/12206922 5) A brief summary of the STEP trials, all 10 of them, which tested semaglutide as a weight loss medications even in non-diabetics: https://diabetes.medicinematters.com/semaglutide/obesity/quick-guide-step-trials/18854832 6) Announcement that the FLOW trial is being stopped prematurely: https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=166327 & https://www.investors.com/news/technology/novo-nordisk-stock-pops-after-hinting-weight-loss-drug-treats-kidney-disease/ 7) GI side effects of GLP-1 receptor agonists: https://doi.org/10.1001/jama.2023.19574 8) Gid M-K's Slate article: https://slate.com/technology/2023/10/exercise-depression-anxiety-treatment-effectiveness-ssris-research.html 9) Study on running to treat depression: https://www.sciencedirect.com/science/article/pii/S0165032723002239?via%3Dihub#s0065:~:text=https%3A//doi.org/10.1016/j.jad.2023.02.064 10) Details on the DEA-Quebec app to find an AED near you: https://www.jacquesdechamplain.com/en/major-update-to-the-dea-quebec-application/ 11) Government of Canada's definition of a pesticide: https://www.canada.ca/en/health-canada/services/environmental-workplace-health/reports-publications/environmental-contaminants/human-biomonitoring-resources/glyphosate-in-people.html   It's Not Twitter, But It'll Do: 1) Jonathan's article on how natural health products and dietary supplements are regulated: https://www.mcgill.ca/oss/article/critical-thinking-health-and-nutrition/false-reassurance-dietary-supplement-regulation 2) Jonathan's article on fentanyl: https://www.mcgill.ca/oss/article/medical-critical-thinking/you-wont-die-touching-fentanyl 3) Chris' article in Medscape about the COSMOS study: https://www.medscape.com/viewarticle/996926 4) Chris' Gazette article on coated vs. uncoated aspirin: https://montrealgazette.com/opinion/columnists/christopher-labos-the-bare-facts-about-coated-aspirin

The market is flooded with claims of miracle weight loss pills and injections.  But which of these medications hold up under scrutiny?  In this episode, Mike discusses the science behind 7 prominent weight loss drugs, providing clarity on their effectiveness, potential side effects, and more. Timestamps: 0:00 - Please leave a review of the show wherever you listen to podcasts and make sure to subscribe! 0:40 - What Are Weight Loss Drugs, How Do They Work, and Why Are They Popular? 6:57 - What Is Orlistat and How Is It Used? 9:54 - How Effective Is Orlistat in Aiding Weight Loss? 12:32 - What Should You Know About Semaglutide? 14:41 - Are There Any Risks or Concerns with Using Semaglutide? 17:35 - Our Biggest Sale of the Year! Save 50% during our Black Friday Sale! https://buylegion.com/ 19:47 - How Does Phentermine Work for Weight Loss? 24:05 - What Is Plenity and What Benefits Does It Offer? 27:56 - What Are the Potential Side Effects of Plenity? 28:21 - How Does Liraglutide Function in Weight Loss? 30:34 - What Are the Side Effects and Risks of Liraglutide? 30:53 - What Is Naltrexone Bupropion and How Is It Used? 32:07 - Are There Side Effects or Risks with Naltrexone/Bupropion? 33:56 - How Does Tirzepatide Aid in Weight Loss? 35:27 - If I Stop Taking Weight Loss Medications, Will I Regain the Lost Weight? Mentioned on the Show: Our Biggest Sale of the Year Is Here! Save 50% during our Black Friday Sale. Go to https://buylegion.com/ and use coupon code MUSCLE to get double reward points!

Ozempic is being hailed as “the end of the Obesity Epidemic.” This week, Mike and Aubrey dig through the sensational claims. But will they make it past the caveats?Links: How a Canadian scientist and a venomous lizard helped pave the way for Ozempic The Discovery and Development of Liraglutide and Semaglutide Ozempic and Wegovy maker courts prominent Black leaders to get Medicare's favor Insurers clamping down on doctors who prescribe Ozempic for weight lossOzempic prescriptions can be easy to get online. Its popularity for weight loss is hurting those who need it most    Glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: real-world evidence from a Mediterranean areaSemaglutide in Patients with Heart Failure with Preserved Ejection Fraction and ObesityReal-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UKSafety of SemaglutideSemaglutide for the treatment of overweight and obesity: A reviewOnce-Weekly Semaglutide in Adolescents with ObesitySemaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary DiseasesReal-World Adherence and Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes Mellitus Patients in the United StatesMedications and conditions associated with weight loss in patients prescribed semaglutide based on real-world dataThanks to Doctor Dreamchip for our lovely theme song!Support the show

A study compared fertility and sexual markers in obese men with low testosterone and erectile dysfunction who took liraglutide, uFSH + HCG, or testosterone. These men were separated into three groups based on their plans for parenthood; results showed impressive improvements on the GLP-1 agonist liraglutide. ResourcesGiagulli VA, Carbone MD, Ramunni MI, et al. Adding liraglutide to lifestyle changes, metformin and testosterone therapy boosts erectile function in diabetic obese men with overt hypogonadism. Andrology. 2015;3(6):1094-1103. doi:10.1111/andr.12099Jensterle M, Podbregar A, Goricar K, Gregoric N, Janez A. Effects of liraglutide on obesity-associated functional hypogonadism in men. Endocr Connect. 2019;8(3):195-202. doi:10.1530/EC-18-0514Latif W, Lambrinos KJ, Rodriguez R. Compare and Contrast the Glucagon-Like Peptide-1 Receptor Agonists (GLP1RAs). In: StatPearls. Treasure Island (FL): StatPearls Publishing; March 27, 2023.La Vignera S, Condorelli RA, Calogero AE, Cannarella R, Aversa A. Sexual and Reproductive Outcomes in Obese Fertile Men with Functional Hypogonadism after Treatment with Liraglutide: Preliminary Results. J Clin Med. 2023;12(2):672. Published 2023 Jan 14. doi:10.3390/jcm12020672Papadakis G. Sex Steroids Balance for Metabolic and Reproductive Health in Klinefelter Syndrome (KLIN-HEALTH). ClinicalTrials.gov identifier: NCT05586802. Updated April 4, 2023. Accessed September 27, 2023. https://www.clinicaltrials.gov/ct2/show/NCT05586802

TestoTribe forum: Testotribe.mn.co

Barely a day goes by without more headlines around new weight-loss drugs, from the issue of global shortages, to investigations into suicide risk, and debate over just how long people will need to be on them. But in this episode of Inside Health we're going to look at something slightly different - and perhaps unexpected. James Gallagher meets lifelong dieter Cheri who has lost just over three stone on semaglutide but she's also noticed other effects from her weekly injection; a calmer mind and a complete lack of desire for her much-loved vapes. She wants to know what's going on – so we seek out some scientists to help us get to the bottom of it. From the evidence gathered so far, are there hints that these drugs could offer potential to treat serious addiction? And have you ever heard of “bed rotting”? It doesn't sound particularly enticing - but James gives it a go in the name of science and we explain all in the programme with the help of two experts. What health questions do you want us to answer? Email the team at insidehealth@bbc.co.uk Declared interests: Professor Giles Yeo: "I have a PhD student part-funded by Novo Nordisk. I consult for Novo Nordisk and Eli Lilly." Dr Tony Goldstone: "I have previously been a member of Data Safety Monitoring Board for clinical trials of Liraglutide for obesity by Novo Nordisk, and have received an honorarium as a conference speaker from Novo Nordisk." Presenter: James Gallagher Producer: Gerry Holt Editor: Erika Wright Production Coordinator: Jonathan Harris Studio Producer: Duncan Hannant (Photo: Cheri Ferguson with her Ozempic pen. Credit Cheri Ferguson)

Diabetes and obesity are on the rise, and there are new tools to help the prevention and management of this twin epidemic of "diabesity" in primary care. Drs Robert Kushner and Tim Garvey discuss. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/982635). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Obesity Treatment & Management https://emedicine.medscape.com/article/123702-treatment Type 2 Diabetes Mellitus https://emedicine.medscape.com/article/117853-overview Diabesity https://diabetesjournals.org/clinical/article/40/4/392/147743/Diabesity National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States https://www.cdc.gov/diabetes/data/statistics-report/index.html Prevalence of Diabetes by Race and Ethnicity in the United States, 2011-2016 https://pubmed.ncbi.nlm.nih.gov/31860047/ Trends in Prevalence of Type 1 and Type 2 Diabetes in Children and Adolescents in the US, 2001-2017 https://pubmed.ncbi.nlm.nih.gov/34427600/ CDC Diabetes and Obesity Maps https://www.cdc.gov/diabetes/data/center/slides.html Diabetes Technology: Standards of Care in Diabetes – 2023 https://pubmed.ncbi.nlm.nih.gov/36507635/ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan – 2022 Update https://pubmed.ncbi.nlm.nih.gov/35963508/ Mediterranean Diet and Obesity-Related Disorders: What Is the Evidence? https://pubmed.ncbi.nlm.nih.gov/36178601/ The Look AHEAD Study: A Description of the Lifestyle Intervention and the Evidence Supporting It https://pubmed.ncbi.nlm.nih.gov/16855180/ Durability of a Primary Care–Led Weight-Management Intervention for Remission of Type 2 Diabetes: 2-Year Results of the DiRECT Open-Label, Cluster-Randomised Trial https://pubmed.ncbi.nlm.nih.gov/30852132/ Semaglutide https://reference.medscape.com/drug/ozempic-rybelsus-wegovy-semaglutide-1000174 Liraglutide https://reference.medscape.com/drug/victoza-saxenda-liraglutide-999449 Tirzepatide Once Weekly for the Treatment of Obesity https://pubmed.ncbi.nlm.nih.gov/35658024/ Glucagon-Like Peptide 1 Receptor Agonists https://www.ncbi.nlm.nih.gov/books/NBK551568/ Dulaglutide Injection https://medlineplus.gov/druginfo/meds/a614047.html Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitors https://www.ncbi.nlm.nih.gov/books/NBK576405/ Incretin Hormones: Their Role in Health and Disease https://pubmed.ncbi.nlm.nih.gov/29364588/ Glucose-Dependent Insulinotropic Polypeptide (GIP) Receptor Antagonists as Anti-Diabetic Agents https://pubmed.ncbi.nlm.nih.gov/29412817/

Episode 59 - Creating Your own Product, TYL's Previous Million Dollar Company, Semaglutide Side Effects, Liraglutide, Shoot Bigger Loads, TRT Telemedicine Ban Show Sponsors www.thetriggeredbrand.com - 15% Off Code - tmt15 www.ultimategymtowel.com - 25% Off Code - tmt25 Test Your Levels Links https://taplink.cc/testyourlevels Youtube Channel - https://www.youtube.com/channel/UCZwSsvti-iVhah5fyfbKwbg Instagram - https://www.instagram.com/testyourlevels/ TikTok - https://www.tiktok.com/@testyourlevels? Sam Stolts Links http://bit.ly/sam-stolt-links Youtube Channel - https://www.youtube.com/channel/UCAOWpCd7-DhAGs8BR3y8_HQ Instagram - https://www.instagram.com/sam.stolt/ TikTok - https://www.tiktok.com/@sam.a.stolt? #MensHealthPodcast #TestosteronePodcast #BodybuildingPodcast

In this episode, Dr. Christopher Tookey and Dr. Rose Wolbrink go through some common misconceptions patients may hear about with regards to some of the new weight loss medications everyone is talking about. This episode is focused on the injectable medications called GLP-1 agonists. Examples inculde Saxenda, Ozempic, Wegovy, Trulicity Mounjaro and Byetta  A disclaimer, we're providing general guidance but everyone is different and you should always discuss with your health care professional management of any disease and therapy before trying anything you discover from a source on the internet (including this podcast) 

The FDA is expected to approve Tirzepatide for weight loss sometime this year and we think it could become the best selling drug of ALL TIME. Today on Dumb Money, we'll weigh the data, size-up the opportunity, and give you the skinny on our diet drug investment thesis. Here are the GLP-1 RA drug makers and their drugs: Eli Lilly (ticker LLY) Tirzepatide sold as Mounjaro for diabetes. Weight loss version expected in 2023. Dulaglutide sold as Trulicity. Novo Nordisk (ticker NVO) Semaglutide sold as Ozempic and Rybelsus for diabetes and Wegovy for weight loss. Liraglutide sold as Victoza for diabetes and Saxenda for weight loss. --- Support this podcast: https://anchor.fm/dumbmoney/support

Dr. Ebell and Dr. Wilkes discuss the POEM titled ' Liraglutide probably the best second drug to prevent cardiovascular events in patients with T2DM who take metformin '

Which glucose-lowering medications work best with metformin? Find out this and more in today's PV Roundup podcast.

Links and study details can be found at www.yourfertilitypharmacist.com